Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18616762 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | March 2024 | October 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18616903 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | March 2024 | October 2024 | Allow | 7 | 1 | 0 | No | No |
| 18610777 | SOLID STATE FORMS OF MAVACAMTEN AND PROCESS FOR PREPARATION THEREOF | March 2024 | January 2025 | Allow | 10 | 3 | 1 | Yes | No |
| 18385582 | 1-(4-BROMOBENZYLIDENEAMINO)-5-PHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | April 2024 | Allow | 5 | 1 | 0 | No | No |
| 18384768 | 1-[4,5-BIS(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]-2-NAPHTHOL AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18384599 | 4,5-BIS(4-BROMOPHENYL)-1-HEXYL-2-(4-NITROPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18378818 | 2-(BENZO[D]THIAZOL-2-YL)-N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18334124 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | June 2023 | January 2024 | Allow | 7 | 2 | 0 | No | No |
| 18334189 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | June 2023 | September 2023 | Allow | 3 | 1 | 0 | No | No |
| 18334209 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | June 2023 | September 2023 | Allow | 3 | 1 | 0 | No | No |
| 18196956 | THERAPEUTIC FORMULATIONS AND USES THEREOF | May 2023 | June 2024 | Abandon | 13 | 2 | 0 | Yes | No |
| 18143166 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | May 2023 | December 2024 | Allow | 20 | 1 | 0 | No | No |
| 18295091 | FARNESOID X RECEPTOR MODULATORS | April 2023 | August 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18128021 | Methods of Treatment of Inflammation Related Conditions Using Pluripotent Anti-Inflammatory and Metabolic Modulators | March 2023 | May 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18175812 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | February 2023 | June 2024 | Allow | 15 | 2 | 0 | No | No |
| 18111161 | HEXADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | February 2023 | May 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18169964 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | February 2023 | August 2024 | Allow | 18 | 2 | 0 | No | No |
| 18157777 | COMPOUND AND METHOD FOR THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE CONDITIONS | January 2023 | May 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18153160 | THERAPEUTIC DNP DERIVATIVES AND METHODS USING SAME | January 2023 | August 2024 | Allow | 19 | 2 | 0 | No | No |
| 18080041 | COMPOSITIONS AND METHODS FOR TREATING CANCER | December 2022 | December 2024 | Allow | 24 | 3 | 0 | Yes | No |
| 18059533 | Modified Tetracycline for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory Processes | November 2022 | September 2024 | Allow | 21 | 2 | 0 | No | No |
| 17977920 | NONRACEMIC MIXTURES AND USES THEREOF | October 2022 | July 2024 | Allow | 21 | 1 | 0 | No | No |
| 18050730 | METHODS FOR ASSEMBLY OF TETRACYCLIC COMPOUNDS BY STEREOSELECTIVE C9-C10 BOND FORMATION | October 2022 | April 2024 | Allow | 26 | 1 | 0 | No | No |
| 17959592 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | October 2022 | November 2023 | Allow | 14 | 0 | 0 | No | No |
| 17952694 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | September 2022 | April 2024 | Allow | 18 | 1 | 0 | No | No |
| 17951129 | STEROIDAL PIPERIDONE DERIVATIVE, SYNTHESIS METHOD, AND USE THEREOF | September 2022 | July 2023 | Allow | 10 | 1 | 0 | No | No |
| 17929273 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | September 2022 | March 2023 | Allow | 6 | 1 | 0 | No | No |
| 17893399 | CONDUCTING REACTIONS IN LEIDENFROST-LEVITATED DROPLETS | August 2022 | September 2024 | Allow | 25 | 1 | 0 | No | No |
| 17806322 | CRYSTALLINE FORMS OF VAMOROLONE | June 2022 | August 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17749976 | OXYSTEROLS AND METHODS OF USE THEREOF | May 2022 | July 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17725331 | USE OF OUABAIN ANTAGONISTS TO INHIBIT VIRAL INFECTION | April 2022 | March 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17718915 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | April 2022 | March 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17714996 | PHARMACEUTICAL COMBINATION COMPRISING AN ALK INHIBITOR AND A SHP2 INHIBITOR | April 2022 | March 2024 | Allow | 23 | 0 | 1 | No | No |
| 17713759 | THERAPEUTIC DNP DERIVATIVES AND METHODS USING SAME | April 2022 | October 2022 | Allow | 7 | 1 | 0 | No | No |
| 17711891 | METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAME | April 2022 | May 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17708159 | PROCESS FOR THE PREPARATION OF CORTEXOLONE 17alpha-PROPIONATE AND NEW HYDRATED CRYSTALLINE FORM THEREOF | March 2022 | December 2024 | Allow | 32 | 4 | 0 | Yes | No |
| 17707303 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | March 2022 | June 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17703877 | COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PARKINSON'S DISEASE | March 2022 | December 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17703331 | GANAXOLONE FOR USE IN TREATING GENETIC EPILEPTIC DISORDERS | March 2022 | August 2023 | Abandon | 17 | 3 | 0 | Yes | No |
| 17703068 | CANNABINOID PRODRUG COMPOUNDS | March 2022 | January 2024 | Allow | 22 | 4 | 1 | Yes | No |
| 17700943 | GLUCOCORTICOID RECEPTOR AGONISTS | March 2022 | June 2023 | Allow | 14 | 2 | 0 | No | No |
| 17700824 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | March 2022 | November 2022 | Allow | 8 | 0 | 0 | No | No |
| 17680553 | Combination Therapy For Prostate Cancer | February 2022 | March 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17592985 | PROCESS FOR THE PREPARATION OF FULVESTRANT | February 2022 | February 2024 | Abandon | 24 | 3 | 0 | No | No |
| 17575731 | NOVEL TRICYCLIC COMPOUNDS | January 2022 | March 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17564400 | FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION | December 2021 | February 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17554808 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | December 2021 | September 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17547496 | Liver Disease | December 2021 | September 2023 | Abandon | 22 | 2 | 0 | Yes | Yes |
| 17539213 | METHOD FOR PREPARING 7ALPHA-METHYL-19-ALDEHYDE-4-ANDROSTENE-3,17-DIONE BY ELECTROCATALYTIC OXIDATION | December 2021 | December 2022 | Allow | 13 | 1 | 0 | No | No |
| 17455538 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA-MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11-DEHYDRODERIVATIVES | November 2021 | November 2023 | Allow | 23 | 1 | 0 | No | No |
| 17609627 | IRRADIATION PROCESS OF PRO VITAMIN D | November 2021 | August 2024 | Allow | 34 | 2 | 1 | No | No |
| 17513733 | NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODS | October 2021 | June 2024 | Abandon | 32 | 5 | 1 | No | No |
| 17506559 | TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH RENAL INSUFFICIENCY | October 2021 | November 2022 | Abandon | 13 | 2 | 0 | No | No |
| 17506561 | TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH RENAL INSUFFICIENCY | October 2021 | November 2022 | Abandon | 13 | 2 | 0 | No | No |
| 17504177 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | October 2021 | October 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17470905 | DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST | September 2021 | December 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17058518 | Preparation Method of Vascular Leakage Blockers With a High Yield | September 2021 | May 2022 | Allow | 18 | 2 | 0 | No | No |
| 17412328 | METHODS AND COMPOSITIONS FOR TREATING ROSACEA | August 2021 | December 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17405984 | Testosterone Ester Triglyceride Formulations | August 2021 | June 2024 | Allow | 34 | 3 | 0 | No | No |
| 17403899 | Bio-catalyzed Synthesis of New Aromatase Inhibitors through Structural Modifications of Anticancer Drug Formestane | August 2021 | February 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17399105 | METHODS OF MAKING CHOLIC ACID DERIVATIVES AND STARTING MATERIALS THEREFOR | August 2021 | March 2022 | Allow | 8 | 2 | 0 | No | No |
| 17398121 | METHOD FOR ENHANCING EXPRESSION OF MOISTURIZING-RELATED SUBSTANCE IN EPIDERMIS | August 2021 | January 2024 | Abandon | 29 | 1 | 0 | Yes | No |
| 17444594 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | August 2021 | August 2023 | Allow | 25 | 1 | 0 | No | No |
| 17396034 | OXYSTEROLS AND METHODS OF USE THEREOF | August 2021 | June 2023 | Allow | 22 | 1 | 0 | No | No |
| 17396464 | A CRYSTALLINE 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID | August 2021 | August 2023 | Allow | 24 | 2 | 0 | No | No |
| 17392004 | NEUROSTERIOD DERIVATIVES AND USES THEREOF | August 2021 | September 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17381829 | NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF | July 2021 | August 2023 | Allow | 25 | 2 | 0 | No | No |
| 17373771 | SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | July 2021 | March 2024 | Allow | 32 | 2 | 0 | No | No |
| 17360614 | PROGESTERONE PHOSPHATE ANALOGS AND USES RELATED THERETO | June 2021 | March 2023 | Allow | 21 | 1 | 0 | No | No |
| 17304778 | 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | June 2021 | April 2024 | Allow | 33 | 2 | 0 | Yes | Yes |
| 17350888 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | June 2021 | November 2021 | Allow | 5 | 1 | 0 | No | No |
| 17351176 | OTIC GEL FORMULATIONS FOR TREATING OTITIS EXTERNA | June 2021 | November 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17341106 | A2A ANTAGONISTS AS COGNITION AND MOTOR FUNCTION ENHANCERS | June 2021 | April 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17319545 | INTERMEDIATES FOR THE PREPARATION OF 11-METHYLENE STEROIDS | May 2021 | October 2024 | Allow | 41 | 1 | 0 | No | No |
| 17307699 | METHOXYCHALCONE DERIVATIVES AND USES THEREOF | May 2021 | November 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17244348 | METHODS OF TREATING PAIN | April 2021 | December 2024 | Allow | 44 | 2 | 0 | No | Yes |
| 17239685 | TOPICAL COMPOSITIONS OF DUTASTERIDE | April 2021 | October 2023 | Allow | 30 | 4 | 0 | No | No |
| 17286524 | 9(11)-UNSATURATED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | April 2021 | December 2024 | Abandon | 43 | 3 | 0 | No | No |
| 17231432 | COMPOSITIONS AND METHODS FOR PROFILING OF GUT MICROBIOTA-ASSOCIATED BILE SALT HYDROLASE (BSH) ACTIVITY | April 2021 | September 2024 | Allow | 41 | 3 | 1 | No | No |
| 17228819 | FARNESOID X RECEPTOR MODULATORS | April 2021 | April 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17282744 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | April 2021 | July 2024 | Allow | 40 | 1 | 0 | No | No |
| 17219940 | Treatment Regimen | April 2021 | February 2024 | Abandon | 34 | 3 | 0 | No | No |
| 17217187 | Methods of Treatment of Inflammation Related Conditions Using Pluripotent Anti-Inflammatory and Metabolic Modulators | March 2021 | April 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17277917 | CH24H INHIBITORS FOR PAIN USE | March 2021 | August 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17199506 | OCULAR FORMULATIONS FOR DRUG-DELIVERY TO THE POSTERIOR SEGMENT OF THE EYE | March 2021 | June 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17192634 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | March 2021 | July 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17186447 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | February 2021 | February 2023 | Allow | 23 | 1 | 0 | No | No |
| 17186272 | Intermediates for the Synthesis of Bile Acid Derivatives, in Particular of Obeticholic Acid | February 2021 | June 2022 | Allow | 16 | 1 | 0 | No | No |
| 17272091 | C19 SCAFFOLDS AND STEROIDS AND METHODS OF USE AND MANUFACTURE THEREOF | February 2021 | June 2023 | Allow | 27 | 1 | 1 | No | No |
| 17178026 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | February 2021 | June 2023 | Allow | 28 | 1 | 0 | No | No |
| 17265577 | COMPOSITION FOR IMPROVING INTESTINAL ENVIRONMENT AND METHOD FOR IMPROVING INTESTINAL FLORA | February 2021 | May 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17164556 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | February 2021 | March 2023 | Allow | 26 | 1 | 0 | No | No |
| 17161920 | NOVEL SALTS AND POLYMORPHS OF SCY-078 | January 2021 | May 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17262915 | FLUORINATED BILE ACID DERIVATIVES | January 2021 | August 2022 | Allow | 18 | 2 | 0 | No | No |
| 17154175 | Methods of Treating Steroid Resistant Diseases and Conditions | January 2021 | October 2023 | Abandon | 33 | 2 | 0 | No | No |
| 17147957 | Aqueous gel composition and its use | January 2021 | June 2023 | Allow | 29 | 1 | 0 | No | No |
| 17134241 | PLEUROMUTILIN URSODEOXYCHOLIC ACID ESTER WITH ANTIBACTERIAL ACTIVITY AND A METHOD OF PREPARING THE SAME | December 2020 | October 2021 | Allow | 10 | 1 | 0 | Yes | No |
| 17122647 | CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3BETA-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVERS DISEASES AND ATHEROSCLEROSIS | December 2020 | March 2023 | Abandon | 27 | 1 | 0 | No | No |
| 16973896 | Modified Tetracycline for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory Processes | December 2020 | August 2022 | Allow | 20 | 2 | 0 | Yes | No |
| 17115095 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | December 2020 | December 2022 | Allow | 24 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BADIO, BARBARA P.
With a 47.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BADIO, BARBARA P works in Art Unit 1628 and has examined 1,099 patent applications in our dataset. With an allowance rate of 51.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner BADIO, BARBARA P's allowance rate of 51.4% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BADIO, BARBARA P receive 2.25 office actions before reaching final disposition. This places the examiner in the 76% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BADIO, BARBARA P is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +25.7% benefit to allowance rate for applications examined by BADIO, BARBARA P. This interview benefit is in the 76% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.1% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 40.9% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 70.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 56% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 64.5% of appeals filed. This is in the 39% percentile among all examiners. Of these withdrawals, 63.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 62.3% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.2% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.2% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.